Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 19/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17619390 | 0.91 | MTNR1A (0.46) | MTNR1AMTNR1BKDM4C | |
| SCHEMBL19268162 | 0.83 | MTNR1A (0.44) | MTNR1AMTNR1BKDM4C | |
| SCHEMBL17602169 | 0.81 | KDM4C (0.63) | KDM4C | |
| SCHEMBL17615603 | 0.81 | KDM4C (0.50) | KDM4C | |
| SCHEMBL29542008 | 0.80 | KDM4C (0.63) | KDM4C | |
| SCHEMBL17602341 | 0.80 | KDM4C (0.52) | KDM4C | |
| SCHEMBL17602147 | 0.80 | KDM4C (0.63) | KDM4C | |
| SCHEMBL17619507 | 0.80 | KDM4C (0.49) | KDM4C | |
| SCHEMBL17602231 | 0.80 | KDM4C (0.59) | KDM4C | |
| SCHEMBL17602267 | 0.79 | KDM4C (0.64) | KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117519-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11535616-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210009585-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10815234-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200199122-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-10208039-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10202381-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20190023704-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| US-10030017-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030017-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-9643965-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643965-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5C, KDM1A | MTNR1A 942/4885MTNR1B 1262/4885KDM4C 9/4885 |
| US-10030017-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | MTNR1A 942/4885MTNR1B 1262/4885KDM4C 9/4885 |
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | MTNR1A 970/4885MTNR1B 1262/4885KDM4C 9/4885 |
| US-11535616-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | MTNR1A 970/4885MTNR1B 1262/4885KDM4C 9/4885 |
| US-20190023704-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | MTNR1A 970/4885MTNR1B 1262/4885KDM4C 9/4885 |
| US-20200199122-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | MTNR1A 970/4885MTNR1B 1262/4885KDM4C 9/4885 |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5C, KDM1A | MTNR1A 942/4885MTNR1B 1262/4885KDM4C 9/4885 |
| US-20230117519-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | MTNR1A 970/4885MTNR1B 1262/4885KDM4C 9/4885 |
| US-10202381-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | MTNR1A 942/4885MTNR1B 1262/4885KDM4C 9/4885 |
| US-20210009585-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | MTNR1A 970/4885MTNR1B 1262/4885KDM4C 9/4885 |
| US-10815234-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | MTNR1A 970/4885MTNR1B 1262/4885KDM4C 9/4885 |
| US-10208039-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | MTNR1A 942/4885MTNR1B 1262/4885KDM4C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.